{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-021527","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2023-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.913048+00:00","generated_at":"2026-06-20T04:05:50.183190+00:00","sec_items":["2.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Vera Therapeutics reports preliminary cash of $114.7M as of Dec 31, 2022","bullets":["Preliminary unaudited cash, cash equivalents and marketable securities total approximately $114.7 million at Dec 31, 2022.","Quarter-end financial close for Q4 2022 is not yet complete; figure is subject to change upon finalization.","No additional financial results, revenue, or earnings data were provided in this filing.","The cash balance excludes any subsequent financing or operating activities through the filing date."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-021527","json":"https://secwatch.observer/filing/0001193125-23-021527.json","markdown":"https://secwatch.observer/filing/0001193125-23-021527.md","text":"https://secwatch.observer/filing/0001193125-23-021527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000119312523021527/0001193125-23-021527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000119312523021527/d413444d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T04:05:50.183190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}